Evidence map›Paper›PMID 34817652›Full record

ArticleHistochemistry and cell biology2022

Focal adhesion kinase splicing and protein activation in papillary thyroid carcinoma progression.

Valentina B Ignjatović, Jelena R Janković Miljuš, Jelena V Rončević, Svetislav B Tatić, Tijana M Išić Denčić, Ilona Đ Đorić, Sonja A Šelemetjev

Abstract read
PubMed Publisher
In one paragraph

Article in Histochemistry and cell biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Anoikis: To Die or Not to Die?International journal of molecular sciences · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. In focus in HCB.Histochemistry and cell biology · 2022
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Valentina B IgnjatovićDepartment of Endocrinology and Radioimmunology, Institute for Application of Nuclear Energy-INEP, University of Belgrade, Banatska 31b, 11080, Zemun-Belgrade, Serbia.
Jelena R Janković MiljušDepartment of Endocrinology and Radioimmunology, Institute for Application of Nuclear Energy-INEP, University of Belgrade, Banatska 31b, 11080, Zemun-Belgrade, Serbia.
Jelena V RončevićDepartment of Endocrinology and Radioimmunology, Institute for Application of Nuclear Energy-INEP, University of Belgrade, Banatska 31b, 11080, Zemun-Belgrade, Serbia.
Svetislav B TatićInsitute of Pathology, Faculty of Medicine, University of Belgrade, dr Subotića starijeg 1, 11000, Belgrade, Serbia.
Tijana M Išić DenčićDepartment of Endocrinology and Radioimmunology, Institute for Application of Nuclear Energy-INEP, University of Belgrade, Banatska 31b, 11080, Zemun-Belgrade, Serbia.
Ilona Đ ĐorićDepartment of Endocrinology and Radioimmunology, Institute for Application of Nuclear Energy-INEP, University of Belgrade, Banatska 31b, 11080, Zemun-Belgrade, Serbia.
Sonja A ŠelemetjevDepartment of Endocrinology and Radioimmunology, Institute for Application of Nuclear Energy-INEP, University of Belgrade, Banatska 31b, 11080, Zemun-Belgrade, Serbia. sonja@inep.co.rs.ORCID http://orcid.org/0000-0002-2898-6671
University of Belgrade · RS

Funding

Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja 451-03-9/2021-14/ 200019
6 · The paper itself

Abstract

Papillary thyroid carcinoma (PTC), a common endocrine malignancy, presents a challenge from a prognostic standpoint. Molecular alterations underlying PTC progression include deregulation of focal adhesion kinase (FAK) at post-transcriptional and post-translational levels. Searching for candidate markers of PTC progression, we investigated the prognostic significance of FAK alterations on mRNA/protein level. The expression levels and subcellular localisation of auto-phosphorylated FAK (pY397-FAK) were determined by western blot (WB) and immunohistochemistry. The quantity of total FAK mRNA, alternatively spliced FAK-Del26 and FAK-Del33 variants were analysed by RT-qPCR and related to pY397-FAK expression and subcellular distribution. The results were correlated with clinicopathological parameters of the patients. The expression of pY397-FAK was significantly elevated in malignant samples. Active FAK showed predominant cytoplasmic distribution with co-occurrence along the membrane, while nuclear staining was found less frequently. Expression of pY397-FAK in separate cellular compartments correlated with adverse clinicopathological parameters, but the strongest association was found when their mean scores were calculated. Alternatively spliced FAK-Del33 and total FAK transcripts positively correlated to pY397-FAK protein levels as well as to characteristics of PTC advancement. Over-expression of FAK on mRNA (total and Del-33) and activated protein (pY397-FAK) levels is a feature of PTC advanced stages. Of the analysed alterations, the mean pY397-FAK IHC score showed the best predictive performance. Correlation between mRNA FAK-Del33 and pY397-FAK expression implies a regulatory role of alternative splicing in PTC patients.

Indexed as

AdolescentAdultAgedAged, 80 and overAlternative SplicingFemaleFocal Adhesion Kinase 1HumansMaleMiddle AgedRNA, MessengerThyroid Cancer, PapillaryYoung AdultFocal Adhesion Kinase 1PTK2 protein, humanRNA, MessengerAlternative splicingFocal adhesion kinasePapillary thyroid carcinomapY397-FAKTumour prognostic factors

Identifiers

PMID34817652
OpenAlexW3216760484

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.